|
You are here: Home: BCU 6|2002: Melody
A Cobleigh,
MD - Select publications
Trastuzumab for the treatment of metastatic breast cancer
Baselga J. Phase I and II clinical trials of trastuzumab.
Ann Oncol 2001;12 Suppl 1:S49-55. Abstract
Bell R. Duration of therapy in metastatic breast cancer:
Management using trastuzumab. Anticancer Drugs 2001;12:561-8.
Abstract
Bell R. Ongoing trials with trastuzumab in metastatic
breast cancer. Ann Oncol 2001;12 Suppl 1:S69- 73. Abstract
Burstein HJ et al. Clinical activity of trastuzumab and
vinorelbine in women with HER2- overexpressing metastatic breast
cancer. J Clin Oncol 2001;19:2722-30. Abstract
Castellon XC et al. Efficacy and safety of 3-weekly trastuzumab
(H) monotherapy in women with HER2-positive metastatic breast cancer
(MBC): Preliminary data from a phase II study. Proc ASCO
2002;Abstract
73.
Cobleigh MA et al. Multinational study of the efficacy
and safety of humanized anti-HER2 monoclonal antibody in women who
have HER2-overexpressing metastatic breast cancer that has progressed
after chemotherapy for metastatic disease. J Clin Oncol
1999;17(9):2639-48. Abstract
Dieras V et al. Interaction between trastuzumab and taxanes.
Oncology 2001;61 Suppl 2:43-9. Abstract
Esteva FJ et al. Phase II study of weekly docetaxel and
trastuzumab for patients with HER-2- overexpressing metastatic breast
cancer. J Clin Oncol 2002;20:1800-8. Abstract
Gelmon K et al. Pharmacokinetics (PK) and safety of trastuzumab
(Herceptin®) when administered every three weeks to women with
metastatic breast cancer. Proc ASCO 2001;Abstract
271.
Harris KA et al. A population pharmacokinetic (PK) model
for trastuzumab and implications for clinical dosing. Proc
ASCO 2002;Abstract
488.
Hortobagyi GN. Overview of treatment results with trastuzumab
(Herceptin) in metastatic breast cancer. Semin Oncol 2001;28:43-7.
Abstract
Leyland-Jones B et al. Serum HER2 levels (shed extracellular
domain) in women with HER2 positive metastatic breast cancer (MBC)
treated with trastuzumab in combination with paclitaxel, both given
every 3 weeks: Preliminary results of a phase II trial. Proc
ASCO 2002;Abstract
1835.
Leyland-Jones B. Dose scheduling--Trastuzumab.
Oncology 2001;61 Suppl 2:31-6. Abstract
Leyland-Jones B et al. Pharmacologic insights into the
future of trastuzumab. Ann Oncol 2001;12 Suppl 1:S43-7.
Abstract
Mackey J et al. Continued use of trastuzumab after disease
progression in women with HER2- positive (HER2+) metastatic breast
cancer (MBC): Results from a retrospective analysis of 105 cases.
Proc ASCO 2002;Abstract
207.
Miller KD et al. Gemcitabine, paclitaxel, and trastuzumab
in metastatic breast cancer. Oncology (Huntingt) 2001;15:38-40.
Abstract
Osoba D, Burchmore M. Health-related quality of life in
women with metastatic breast cancer treated with trastuzumab (Herceptin).
Semin Oncol 1999;26:84-8. Abstract
Pegram MD. Docetaxel and Trastuzumab: Foundation for future
strategies. Oncologist 2001;6 Suppl 3:22-5. Abstract
Pegram MD, Slamon DJ. Combination therapy with trastuzumab
(Herceptin) and cisplatin for chemoresistant metastatic breast cancer:
Evidence for receptor-enhanced chemosensitivity. Semin
Oncol 1999;26:89-95. Abstract
Piccart MJ. Proposed treatment guidelines for HER2-positive
metastatic breast cancer in Europe. Ann Oncol 2001;12 Suppl
1:S89-94. Abstract
Seidman A et al. Cardiac dysfunction in the trastuzumab
clinical trials experience. J Clin Oncol 2002;20:1215-21.
Abstract
Seidman AD et al. Weekly trastuzumab and paclitaxel therapy
for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype
and gene amplification. J Clin Oncol 2001;19:2587- 95.
Abstract
Slamon DJ et al. Use of chemotherapy plus a monoclonal
antibody against HER2 for metastatic breast cancer that overexpresses
HER2. N Engl J Med 2001;344:783-92. Abstract
Smith IE. Efficacy and safety of trastuzumab in women
with metastatic breast cancer: Results from pivotal clinical studies.
Anticancer Drugs 2001;12 Suppl 4:S3-10. Abstract
Thomssen C. Trials of new combinations of trastuzumab
in metastatic breast cancer. Anticancer Drugs 2001;12 Suppl
4:S19-25. Abstract
Vogel CL et al. Efficacy and safety of trastuzumab as
a single agent in first-line treatment of HER2- overexpressing metastatic
breast cancer. J Clin Oncol 2002;20:719-26. Abstract
Winer EP, Burstein HJ. New combinations with trastuzumab
in metastatic breast cancer. Oncology 2001;61 Suppl 2:50-7.
Abstract
|
